J
J.M.M. Gijtenbeek
Researcher at Radboud University Nijmegen
Publications - 37
Citations - 7813
J.M.M. Gijtenbeek is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Temozolomide & Internal medicine. The author has an hindex of 19, co-authored 34 publications receiving 6769 citations. Previous affiliations of J.M.M. Gijtenbeek include Memorial Sloan Kettering Cancer Center & Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
Cyclosporine neurotoxicity: a review.
TL;DR: Dose reduction or withdrawal of CsA usually results in resolution of clinical symptoms and of neuroimaging abnormalities, and Neurotoxicity is more frequent with high C'sA blood levels, but levels may be within the therapeutic range.
Journal ArticleDOI
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert,Brigitta G. Baumert,Monika E. Hegi,Martin J. van den Bent,Andreas von Deimling,Thierry Gorlia,Khê Hoang-Xuan,Alba A. Brandes,Guy Kantor,Martin J.B. Taphoorn,Mohamed Ben Hassel,Christian Hartmann,Christian Hartmann,Gail Ryan,David Capper,Johan M. Kros,Sebastian Kurscheid,Sebastian Kurscheid,Wolfgang Wick,Roelien H. Enting,Michele Reni,Brian Thiessen,Frédéric Dhermain,Jacoline E C Bromberg,Loïc Feuvret,Jaap C. Reijneveld,Olivier Chinot,J.M.M. Gijtenbeek,John P. Rossiter,Nicolas Dif,Carmen Balana,Jose Bravo-Marques,Paul Clement,Christine Marosi,Tzahala Tzuk-Shina,Robert A Nordal,Jeremy Rees,Denis Lacombe,Warren P. Mason,Roger Stupp,Roger Stupp +40 more
TL;DR: There was no significant difference in outcome of the overall patient population treated with either radiotherapy alone or TMZ chemotherapy alone, and further data maturation is needed for overall survival analyses and evaluation of the full predictive impact of the molecular subtypes for individualized treatment choices.
Journal ArticleDOI
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
H. J. Dubbink,Walter Taal,R.M. van Marion,Johan M. Kros,I. van Heuvel,Jacoline E C Bromberg,B. A. Zonnenberg,C. B. L. Zonnenberg,Tjeerd J. Postma,J.M.M. Gijtenbeek,Willem Boogerd,F. H. Groenendijk,F. H. Groenendijk,Pa. E. Sillevis Smitt,W. N. M. Dinjens,M. J. van den Bent +15 more
TL;DR: Investigating the correlation of IDH1 and IDH2 mutations with overall survival and response to temozolomide in a cohort of patients with dedifferentiated low-grade astrocytomas indicates that IDH 1 mutations identify a subgroup of gliomas with an improved survival, but are unrelated to the temozoomide response.
Journal ArticleDOI
Westeinde Sciatica Trial: randomized controlled study of bed rest and physiotherapy for acute sciatica
Derk J Hofstee,J.M.M. Gijtenbeek,P.H. Hoogland,Hans C. van Houwelingen,Alfred Kloet,Freek Lötters,Joseph Th. J. Tans +6 more
TL;DR: Bed rest and physiotherapy are not more effective in acute sciatica than continuation of ADLs.